XORTX Short Long Term Debt Total from 2010 to 2024

XRTX Stock  USD 1.21  0.03  2.54%   
XORTX Therapeutics Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total will likely drop to about 10.9 K in 2024. During the period from 2010 to 2024, XORTX Therapeutics Short and Long Term Debt Total regression line of annual values had r-squared of  0.32 and arithmetic mean of  99,346. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2017-09-30
Previous Quarter
83.7 K
Current Value
61.5 K
Quarterly Volatility
67.6 K
 
Covid
Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 1 M, Other Operating Expenses of 2.4 M or Total Operating Expenses of 2.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.
  
Check out the analysis of XORTX Therapeutics Correlation against competitors.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of XORTX Therapeutics over the last few years. It is XORTX Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

XORTX Short Long Term Debt Total Regression Statistics

Arithmetic Mean99,346
Geometric Mean75,872
Coefficient Of Variation64.08
Mean Deviation46,211
Median124,127
Standard Deviation63,663
Sample Variance4.1B
Range261.5K
R-Value(0.57)
Mean Square Error3B
R-Squared0.32
Significance0.03
Slope(8,056)
Total Sum of Squares56.7B

XORTX Short Long Term Debt Total History

202410.9 K
202311.5 K
202077.4 K
201950.8 K
201843.3 K
2017272.5 K

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total11.5 K10.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.